Here are three things to know:
1. Lattice Biologics’ Next Generation Allograft Technology is based on decellularized human Extracellular Matrix, a biological substrate for the company’s allografts.
2. The ECM-based allograft technology is derived from native ECM secreted by human mesenchymal stem cells.
3. The company’s allograft products are designed for several clinical applications, including enhancing spinal fusion.
More articles on biologics:
8 key surgeon Q&As on biologics in orthopedics & spine
International Stem Cell Corp. to launch joint supplement for osteoarthritis pain in Q3 2018
How Dr. Kevin Stone helped Super Bowl champion Tracy Porter make a comeback — 6 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.